An essential role for the circadian-regulated gene Nocturnin in osteogenesis: The importance of local timekeeping in skeletal homeostasis

Annals of the New York Academy of Sciences

Volumn 1237, Issue 1, 2011, Pages 58-63

  Guntur, Anyonya R ^a   Kawai, Masanobu ^b   Le, Phuong ^a   Bouxsein, Mary L ^c   Bornstein, Sheila ^a   Green, Carla B ^d   Rosen, Clifford J ^a  

^a Maine Medical Center Research Institute   (United States)

^b RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Nocturnin; PPAR ; Rosiglitazone

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; OSTEOCALCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; TRANSCRIPTION FACTOR OSTERIX;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; C57BL 6 MOUSE; CELL FATE; CIRCADIAN RHYTHM; CONTROLLED STUDY; GENE; HOMEOSTASIS; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MOUSE; NOCTURNIN GENE; NONHUMAN; OSSIFICATION; OSTEOLYSIS;

MUS;

EID: 81255210494     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06213.x     Document Type: Article

References (21)

1. Phinney, D.G. & D.J. Prockop 2007. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 25: 2896-2902.
2. Nuttall, M.E. & J.M. Gimble 2004. Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications. Curr. Opin. Pharmacol. 4: 290-294.
3. Fu, L., M.S. Patel, et al 2005. The molecular clock mediates leptin-regulated bone formation. Cell 122: 803-815.
4. Froy, O. 2010. Metabolism and circadian rhythms-implications for obesity. Endocrine Rev. 31: 1-24.
5. Maronde, E., A.F. Schilling, et al 2010. The clock genes period 2 and cryptochrome 2 differentially balance bone formation. PLoS One 5: e11527.
6. Fu, L., et al 2005. The molecular clock mediates leptin-regulated bone formation. Cell 122: 803-815.
7. Green, C.B. & J.C. Besharse, 1996. Identification of a novel vertebrate circadian clock-regulated gene encoding the protein nocturnin. Proc. Natl. Acad. Sci. 93: 14884-14888.
8. Garbarino-Pico, E., et al 2007. Immediate early response of the circadian polyA ribonuclease nocturnin to two extracellular stimuli. RNA 13: 745-755.
9. Kawai, M., C.B. Green, et al 2010. Nocturnin: a circadian target of Pparg-induced adipogenesis. Ann. N. Y. Acad. Sci. 1192: 131-138.
10. Goldstrohm, A.C. and M. Wickens 2008. Multifunctional deadenylase complexes diversify mRNA control. Nat. Rev. Mol. Cell Biol. 9: 337-344.
11. Kawai, M., C.B. Green, et al 2010. A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-γ nuclear translocation. Proc. Natl. Acad. Sci. 107: 10508-10513.
12. Green, C.B., N. Douris, et al 2007. Loss of Nocturnin, a circadian deadenylase, confers resistance to hepatic steatosis and diet-induced obesity. Proc. Natl. Acad. Sci. 104: 9888-9893.
13. McLeod, M.J. 1980. Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology 22: 299-301.
14. Livak, K.J. and T.D. Schmittgen 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-[Delta][Delta]CT method. Methods 25: 402-408.
15. Guntur, A.R., M.I. Reinhold, et al 2011. Conditional ablation of Pten in osteoprogenitors stimulates FGF signaling. Development 138: 1433-1444.
16. Douris, N., S. Kojima, et al 2011. Nocturnin regulates circadian trafficking of dietary lipid in intestinal enterocytes. Curr. Biol. 21: 1347-1355.
17. Teplyuk, N.M., Y. Zhang, et al 2009. The osteogenic transcription factor Runx2 controls genes involved in sterol/steroid metabolism, including Cyp11a1 in osteoblasts. Mol. Endocrinol. 23: 849-861.
18. Acimovic, J., M. Fink, et al 2008. CREM modulates the circadian expression of CYP51, HMGCR and cholesterogenesis in the liver. Biochem. Biophys. Res. Commun. 376: 206-210.
19. Rzonca, S.O., L.J. Suva, et al 2004. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 145: 401-406.
20. Kawai, M., A.M. Delany, et al 2010. Nocturnin suppresses Igf1 expression in bone by targeting the 3' untranslated region of Igf1 mRNA. Endocrinology 151: 4861-4870.
21. Keber, R., H. Motaln, et al 2011. Mouse knockout of the cholesterogenic cytochrome P450 lanosterol 14α-Demethylase (CYP51) resembles Antley-Bixler syndrome. J. Biol. Chem. 286: 29086-29097.